Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as Eli Lilly, Pfizer, and Roche are advancing drugs through various clinical stages, including promising late-stage candidates like retatrutide and olatorepatide. Innovations include oral formulations and multi-receptor agonists aiming to improve efficacy and patient convenience. Recent trial successes and regulatory approvals suggest these therapies will expand treatment options and market growth in coming years.

As of Nov 12, 2026 01:12 WIB, Pfizer (PFE) shares trade at USD 29.23 with a slight 0.43% decline in one day on Pluang, while Eli Lilly (LLY) is priced at USD 1,427.45, down 0.34% in the same period. Despite the minor daily drops, Pfizer maintains a strong dividend yield of 5.86%, and Eli Lilly holds a massive market cap of $1.26 trillion. The ongoing development of GLP-1 receptor agonists and incretin therapies by these companies is reflected in active investor interest, with Pfizer seeing 82% buy orders on Pluang.